#USA #Chicago #metastatic cancer #Penetrium #Hyundai Bioscience

Breaking New Ground in Oncology: Penetrium™

At the recent American Association for Cancer Research (AACR) Annual Meeting held in Chicago, Hyundai Bioscience revealed significant advancements in cancer treatment through their innovative therapy, Penetrium™. This new approach tackles the longstanding challenges presented by cold tumors and metastatic cancer, presenting a promising alternative to traditional immunotherapies.

Understanding Cold Tumors and the Role of Penetrium™

Historically, the limitations of immunotherapy and antibody therapies in treating cold tumors have been attributed to genetic mutations within the tumors. However, Hyundai Bioscience’s research challenges this narrative, proposing that the real issue lies in a phenomenon known as pseudo-resistance. This is a structural barrier caused by the stiffening of the extracellular matrix (ECM), which hinders the infiltration of immune cells and therapeutic agents into the tumor's core.

In an astonishing breakthrough, the studies demonstrated that Penetrium™ can effectively remodel the ECM, thereby restoring the necessary pathways for drug and immune cell access. This unprecedented structural solution holds the promise of transforming how cold tumors are approached in clinical settings.

Clinical Success in Multiple Cancer Models

Hyundai Bioscience's preclinical trials presented compelling data from several cancer models, particularly in triple-negative breast cancer (TNBC) and metastatic lung cancer.

1. Combination with Immunotherapy: In TNBC mouse models, Penetrium™'s combination with anti-PD-1 therapies resulted in a remarkable 48.3% decrease in tumor burden compared to treatments using anti-PD-1 alone, which did not eliminate metastasis. The combination treatment induced necrosis within three days, continuing to expand with subsequent doses.

2. Combining with Antibody Therapy: In metastatic lung cancer models, the standard bevacizumab therapy displayed only a 33% reduction in metastasis. Yet, when paired with Penetrium™, the treatment achieved a striking 0% lung metastasis at a dosage of 100 mg/kg. Molecular analyses confirmed that ECM normalization facilitated improved drug penetration in treated subjects.

3. Enhancing Chemotherapy Efficacy: In Paclitaxel assays, which previously exacerbated lung metastasis, the Penetrium™ combination yielded a significant reduction in metastatic lesions by over 70-80%, while also suppressing MMP-9 levels and enhancing the structural integrity of cellular junctions.

Expanding Horizons: Validations in Naturally Occurring Conditions

Further validation of Penetrium™'s efficacy was provided through a natural canine mammary cancer model, where combinations of Penetrium™ and POLYTAXEL® resulted in a primary tumor volume reduction of up to 38.7%, significantly outperforming monotherapy approaches. Even metastatic lymph node involvement showed a compelling 78.99% reduction in tumor volume, further underscoring the treatment's potency.

Proven Safety and Future Directions

Remarkably, the safety profile of Penetrium™ has been established, with administrations at less than 9% of the NOAEL in a comprehensive 13-week toxicity study. Moreover, its safety has been confirmed through its previous application in a Phase 2 trial for COVID-19.

Hyundai Bioscience’s Head of Research, Dr. Soo-Jung Kim, emphasized the transformative potential of Penetrium™. "This is the first platform capable of addressing infiltration failures associated with cold tumors. With our groundbreaking combination studies achieving outstanding results, we are poised to launch clinical trials focusing on TNBC and metastatic lung cancer shortly."

Clinical Expansion and Future Perspectives

The company has announced plans to initiate a Phase 1 trial for prostate cancer in South Korea and is preparing an investigator-initiated trial for acute myeloid leukemia (AML) in France. Notably, Penetrium™ is on the cusp of launching a tumor-agnostic cancer treatment platform, applicable not just to TNBC and metastatic lung cancers, but also to other challenging cancer types such as pancreatic and ovarian cancers, redefining the landscape of oncological treatment.

About Hyundai Bioscience

Hyundai Bioscience is committed to pioneering innovative treatments targeting cancer and viral diseases. Their dedication is exemplified through Penetrium™ ECM Remodeling Therapy™, which aims to redefine cancer treatment accessibility and effectiveness. The company continues to shape the future with an unwavering belief that no condition is beyond treatment. Through groundbreaking research and international collaborations, Hyundai Bioscience is at the forefront of therapeutic advancements that promise new hope for patients around the globe.